PhRMA's fortunes may be shifting
As Democrats take control of the House this January, the drug industry’s largest trade group may struggle to hold onto its traditional level of clout, as more than a dozen lobbyists and former staffers told STAT’s Nicholas Florko.
One of the biggest concerns is that PhRMA doesn’t yet have a strategy that can win over left-leaning legislators — and can’t win favor anymore with some lawmakers through donations; many Democrats have publicly pledged to not accept money from corporate PACs or the drug industry.
.png)
No hay comentarios:
Publicar un comentario